I have sufficient retrieved content plus comprehensive knowledge to deliver a thorough answer. Here is the full MD exam answer:
Endocrine Findings in Tuberculosis — Full Details (MD Exam, 15 Marks)
Introduction
Tuberculosis (TB) is a systemic granulomatous infection caused by Mycobacterium tuberculosis that can involve virtually every endocrine gland through hematogenous spread, direct extension, or immune-mediated mechanisms. Endocrine involvement is often underdiagnosed and may be the dominant clinical presentation in extrapulmonary TB.
1. ADRENAL TUBERCULOSIS — Most Important Endocrine Manifestation
Pathology
- TB is historically the most common cause of primary adrenal insufficiency (Addison's disease) worldwide, though autoimmune adrenalitis now predominates in developed countries
- Bilateral adrenal involvement occurs via hematogenous spread
- Caseous necrosis → fibrosis → calcification → destruction of cortex (>90% of cortex must be destroyed before insufficiency manifests)
- Both glucocorticoid and mineralocorticoid secretion are lost (primary adrenal insufficiency)
Clinical Features
| Feature | Mechanism |
|---|
| Fatigue, weakness, weight loss | Cortisol deficiency |
| Hyperpigmentation (skin, mucosa, scars, pressure points) | ↑ ACTH/MSH (negative feedback lost) |
| Postural hypotension, salt craving | Mineralocorticoid (aldosterone) deficiency |
| Nausea, vomiting, abdominal pain | Cortisol deficiency |
| Hyponatremia, hyperkalemia | Aldosterone deficiency |
| Hypoglycemia | Cortisol deficiency |
| Eosinophilia | Cortisol deficiency (loss of suppression) |
| Adrenal crisis (precipitated by stress) | Acute cortisol + mineralocorticoid loss |
Diagnosis
- Serum cortisol (8 AM): <3 µg/dL = diagnostic; <18 µg/dL on stimulation = abnormal
- Short Synacthen (ACTH stimulation) test: Gold standard — 250 µg cosyntropin IV/IM; measure cortisol at 0, 30, 60 min; peak <18 µg/dL = primary adrenal insufficiency
- Plasma ACTH: Elevated (>2× upper limit) in primary AI
- Serum electrolytes: Hyponatremia, hyperkalemia
- CT abdomen: Bilateral adrenal enlargement (active TB) → later bilateral calcification (pathognomonic of old TB)
- Adrenal biopsy (if needed): Caseating granulomas, AFB
Treatment — Adrenal TB
A. Antitubercular Therapy (ATT)
Standard 6-month regimen (2HRZE/4HR):
| Phase | Drugs | Duration |
|---|
| Intensive phase | Isoniazid (H) + Rifampicin (R) + Pyrazinamide (Z) + Ethambutol (E) | 2 months |
| Continuation phase | Isoniazid (H) + Rifampicin (R) | 4 months |
Daily Doses (Adult, weight-based):
| Drug | Daily Dose | Max Dose |
|---|
| Isoniazid (H) | 5 mg/kg/day | 300 mg/day |
| Rifampicin (R) | 10 mg/kg/day | 600 mg/day |
| Pyrazinamide (Z) | 25 mg/kg/day | 2000 mg/day |
| Ethambutol (E) | 15 mg/kg/day | 1600 mg/day |
Note: Rifampicin significantly induces CYP3A4 and accelerates cortisol metabolism — hydrocortisone dose may need to be increased by 2–3× during rifampicin therapy.
B. Hormone Replacement Therapy (MANDATORY — lifelong)
Glucocorticoid replacement:
| Drug | Dose | Timing |
|---|
| Hydrocortisone (preferred) | 15–20 mg in AM + 5–10 mg in early PM | Mimics diurnal rhythm |
| Prednisolone (alternative) | 5 mg AM + 2.5 mg PM | Once/twice daily |
Mineralocorticoid replacement (primary AI):
| Drug | Dose |
|---|
| Fludrocortisone | 50–200 µg/day orally |
Sick day rules:
- Minor illness/fever: Double glucocorticoid dose
- Major illness/surgery: Hydrocortisone 50–100 mg IV/IM q6–8h (stress dosing)
- Adrenal crisis: Hydrocortisone 100 mg IV bolus → 50–100 mg IV q6–8h + IV normal saline 1L in 1st hour + glucose
2. SIADH (Syndrome of Inappropriate ADH Secretion)
Mechanism
- Pulmonary TB → ectopic ADH production from lung tissue or hypothalamic stimulation
- Tuberculous meningitis → direct hypothalamic/pituitary involvement
- Result: Free water retention → dilutional hyponatremia (euvolemic)
Features
- Hyponatremia (Na⁺ <135 mEq/L), serum hypo-osmolality (<275 mOsm/kg)
- Urine Na⁺ >20 mEq/L, urine osmolality >100 mOsm/kg (inappropriately concentrated)
- Normal/expanded plasma volume (no edema, no dehydration)
- Neurological symptoms: headache, confusion, seizures (if Na⁺ <120 mEq/L)
Treatment
- Treat underlying TB (ATT as above) — SIADH resolves with treatment
- Fluid restriction: 800–1000 mL/day (first-line for mild-moderate SIADH)
- For severe/symptomatic hyponatremia (Na⁺ <120 or seizures): Hypertonic saline (3% NaCl) IV — correct Na⁺ at rate ≤8–10 mEq/L per 24 hours (to prevent osmotic demyelination syndrome)
- Demeclocycline 300–600 mg BD (blocks ADH at collecting duct) — if fluid restriction fails
3. HYPERCALCEMIA
Mechanism
- Activated macrophages in TB granulomas express 1-α hydroxylase (CYP27B1) → converts 25-OH vitamin D to 1,25-(OH)₂ vitamin D (calcitriol) in an unregulated fashion (not subject to normal feedback)
- ↑ Calcitriol → ↑ intestinal calcium absorption + ↑ bone resorption → hypercalcemia
- Granulomatous hypercalcemia: seen in ~10% of TB patients; hypercalciuria more common
Features
- "Bones, stones, groans, psychic moans" (hypercalcemia symptoms)
- Polyuria, polydipsia (nephrogenic DI from hypercalcemia)
- Nephrolithiasis, nephrocalcinosis
- Low PTH (suppressed), elevated calcitriol
Treatment
- ATT (primary treatment — resolves hypercalcemia as granulomas heal)
- Hydration: IV normal saline 200–300 mL/hour
- Glucocorticoids: Prednisolone 40–60 mg/day (inhibit macrophage 1-α hydroxylase) — highly effective in granulomatous hypercalcemia
- Avoid: Calcium supplements, vitamin D, thiazide diuretics, sunlight exposure (all worsen hypercalcemia)
- Bisphosphonates if refractory
4. THYROID INVOLVEMENT
Mechanisms & Types
| Type | Details |
|---|
| Tuberculous thyroiditis | Rare; direct mycobacterial infection of thyroid; presents as cold abscess or thyroid mass |
| Transient thyrotoxicosis | Granulomatous destruction → release of preformed thyroid hormone |
| Hypothyroidism | Destruction of thyroid tissue by caseating granuloma |
| Drug-induced hypothyroidism | PAS (para-aminosalicylic acid — second-line ATT) inhibits thyroid peroxidase |
| Non-thyroidal illness (sick euthyroid) | ↓ T3, ↓/normal T4, ↓ TSH — in severe TB; not true hypothyroidism |
Diagnosis
- TFTs: TSH, Free T3, Free T4
- Thyroid ultrasound/FNAC: Caseating granulomas, AFB on ZN stain
- Cold nodule on scintigraphy
Treatment
- ATT is primary treatment for tuberculous thyroiditis
- Transient thyrotoxicosis: Beta-blocker (propranolol 40–80 mg TDS) for symptom relief; antithyroid drugs NOT effective (no hypersynthesis)
- PAS-induced hypothyroidism: Levothyroxine 25–50 µg/day titrated up; stop PAS if feasible
5. PITUITARY AND HYPOTHALAMIC TB
Pathology
- Hematogenous seeding or extension from tuberculous meningitis
- Tuberculoma in sella turcica or suprasellar region
- Basal meningitis → infundibular involvement
Clinical Features
| Axis Affected | Manifestation |
|---|
| ADH (most common) | Central Diabetes Insipidus (DI) — polyuria, polydipsia, hypernatremia |
| ACTH | Secondary adrenal insufficiency (no hyperpigmentation, aldosterone relatively preserved) |
| TSH | Central hypothyroidism — low FT4, inappropriately normal/low TSH |
| Gonadotropins (FSH/LH) | Hypogonadotropic hypogonadism — amenorrhea, infertility, ↓ libido |
| GH | Growth hormone deficiency — short stature (children), metabolic syndrome (adults) |
| Prolactin | Hyperprolactinemia (stalk compression → loss of dopamine inhibition) → galactorrhea, amenorrhea |
| Mass effect | Bitemporal hemianopia (chiasmal compression), headache |
Treatment
- ATT (6–12 months; extend to 12 months for CNS TB)
- Central DI: Desmopressin (DDAVP):
- Intranasal: 10–40 µg/day in 1–2 divided doses
- Oral: 0.05–1.2 mg/day
- IV/SC: 1–4 µg/day
- Hormone replacement: Replace each deficient axis individually (as above)
- Corticosteroids for CNS TB: Dexamethasone 0.4 mg/kg/day for 2 weeks, then tapered over 4 weeks (WHO recommended for TB meningitis)
- Surgical decompression if visual compromise persists despite ATT
6. HYPOGONADISM IN TB
Mechanism
- Systemic illness effect: Chronic inflammation suppresses GnRH → hypogonadotropic hypogonadism
- Direct testicular/ovarian involvement: Rare; miliary TB
- Malnutrition in TB → hypothalamic amenorrhea
Features
- Oligomenorrhea/amenorrhea in women
- Reduced testosterone, libido, spermatogenesis in men
- Infertility
Treatment
- Primarily resolves with ATT and nutritional rehabilitation
- Hormone replacement if persistent after TB treatment
7. PANCREATIC TB AND GLUCOSE DYSREGULATION
TB and Diabetes Mellitus — Bidirectional Relationship
- DM triples the risk of TB (impaired macrophage function, reduced T-cell immunity)
- TB worsens glycemic control (cytokine-mediated insulin resistance, catabolic state)
- Pancreatic TB (rare): caseous granulomas → pancreatic insufficiency
TB Drug Effects on Glucose
| Drug | Effect |
|---|
| Rifampicin | ↓ Sulfonylurea levels (induces CYP2C9) → worsens glycemic control |
| Isoniazid | Can cause hyperglycemia (inhibits insulin secretion) |
| Pyrazinamide | Mild hyperuricemia, occasional glucose effects |
Management
- Optimize glycemic control (target HbA1c <7–8% in TB-DM)
- Insulin preferred during intensive phase of ATT
- Monitor sulfonylurea/OHA efficacy if rifampicin used
8. ELECTROLYTE AND METABOLIC DISTURBANCES SUMMARY
| Abnormality | Mechanism | Frequency |
|---|
| Hyponatremia | SIADH, adrenal insufficiency, salt wasting | Common |
| Hyperkalemia | Primary adrenal insufficiency (aldosterone deficiency) | With adrenal TB |
| Hypercalcemia | Granulomatous 1-α hydroxylation | ~10% |
| Hypercalciuria | Same mechanism | >Hypercalcemia |
| Hypokalemia | Rifampicin-induced Fanconi syndrome (rare) | Rare |
| Hyperuricemia | Pyrazinamide (inhibits urate excretion) | Common with PZA use |
Standard ATT Regimen — Quick Reference Card
First-Line Drugs (Daily Doses — Adult)
| Drug | Daily Dose | Key Toxicity | Monitoring |
|---|
| Isoniazid (H) | 5 mg/kg (max 300 mg) | Hepatotoxicity, peripheral neuropathy | LFTs, add pyridoxine 25 mg/day |
| Rifampicin (R) | 10 mg/kg (max 600 mg) | Hepatotoxicity, drug interactions, orange urine | LFTs, drug interactions |
| Pyrazinamide (Z) | 25 mg/kg (max 2 g) | Hepatotoxicity, hyperuricemia, arthralgia | Uric acid, LFTs |
| Ethambutol (E) | 15 mg/kg (max 1.6 g) | Optic neuritis (color vision, acuity) | Monthly visual acuity testing |
Regimen Duration by Site
| TB Site | Regimen | Duration |
|---|
| Pulmonary, lymph node | 2HRZE / 4HR | 6 months |
| Adrenal, abdominal | 2HRZE / 4HR | 6 months |
| Bone, joint | 2HRZE / 4HR | 9 months |
| CNS (meningitis, tuberculoma) | 2HRZE / 10HR + dexamethasone | 12 months |
| Miliary TB | 2HRZE / 4HR | 6 months |
Key Points for MD Exam
- Adrenal TB is the most important endocrine manifestation; TB was historically the leading cause of Addison's disease worldwide.
- Bilateral adrenal calcification on CT is pathognomonic of healed adrenal TB.
- Rifampicin accelerates cortisol metabolism via CYP3A4 — hydrocortisone dose must be increased during ATT.
- SIADH occurs in pulmonary TB and TB meningitis — hyponatremia is the most common electrolyte abnormality.
- Hypercalcemia in TB is granulomatous — low PTH, elevated calcitriol, responds dramatically to steroids and ATT.
- Central DI is the most common pituitary axis affected in hypothalamic-pituitary TB.
- Sick euthyroid syndrome (low T3) is common in severe TB — does not require treatment; resolves with ATT.
- DM and TB have a bidirectional relationship; rifampicin reduces OHA efficacy.
- Pyridoxine (25 mg/day) must be co-administered with isoniazid to prevent peripheral neuropathy.
- Fludrocortisone is always needed in primary adrenal insufficiency (adrenal TB) — not in secondary (pituitary TB).
Sources: Harrison's Principles of Internal Medicine, 21st Edition (p. 10827); Treatment of Drug-Susceptible Tuberculosis — IDSA/ATS/CDC Guidelines; WHO Guidelines for Treatment of TB (2022); supplemented with core endocrinology and infectious disease knowledge.